A Look At CMS' Proposed Medicaid Drug Rebate Changes
By Tom Bulleit, Scott Falin and Joanna Hwang (July 9, 2020, 4:39 PM EDT) -- On June 17, the Centers for Medicare & Medicaid Services issued a proposed rule that, if finalized, would modify significantly the current Medicaid Drug Rebate Program regulations, which have been generally (but not entirely) long favored by drugmakers.
The proposed rule puts forth new regulatory policies, as well as provides clarification with regard to already established polices, intended to encourage drug manufacturers and states to participate in value-based purchasing arrangements, or VBPs.
Significantly, the proposed rule impacts best-price reporting in VBPs, excludes pharmacy benefit managers accumulator programs from best-price and average-manufacturer-price determinations, and updates the definitions of several relevant terms to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!